CUI JINGRONG JEAN (Chief Scientific Officer) sold 5.9% of their position (55.50K shares) of TURNING POINT THERAPEUTICS, INC. on the open market
Open‑market sale worth $3.04M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−300.00
Price / share
$54.00
Trade value
$16.20K
% of position
Common Stock
Shares
−400.00
Price / share
$55.75
Trade value
$22.30K
% of position
Common Stock
Shares
−4.25K
Price / share
$56.79
Trade value
$241.36K
% of position
Common Stock
Shares
−10.53K
Price / share
$57.95
Trade value
$609.92K
% of position
Common Stock
Shares
−1.29K
Price / share
$58.38
Trade value
$75.37K
% of position
Common Stock
Shares
−1.73K
Price / share
$58.83
Trade value
$102.01K
% of position
Common Stock
Shares
−7.91K
Price / share
$52.49
Trade value
$414.99K
% of position
Common Stock
Shares
−10.19K
Price / share
$53.11
Trade value
$541.40K
% of position
Common Stock
Shares
−400.00
Price / share
$54.21
Trade value
$21.68K
% of position
Common Stock
Shares
−3.39K
Price / share
$52.44
Trade value
$177.77K
% of position
Common Stock
Shares
−5.01K
Price / share
$53.30
Trade value
$266.98K
% of position
Common Stock
Shares
−10.10K
Price / share
$54.06
Trade value
$546.06K
% of position
Net shares
−55.50K
Net value
-$3.04M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 1/10/2020 | S · Sale | −300.00 | $54.00 | $16.20K | 0.0% | 936.22K | 935.92K |
| Common Stock Indirect | 1/10/2020 | S · Sale | −400.00 | $55.75 | $22.30K | 0.0% | 935.92K | 935.52K |
| Common Stock Indirect | 1/10/2020 | S · Sale | −4.25K | $56.79 | $241.36K | 0.5% | 935.52K | 931.27K |
| Common Stock Indirect | 1/10/2020 | S · Sale | −10.53K | $57.95 | $609.92K | 1.1% | 931.27K | 920.74K |
| Common Stock Indirect | 1/10/2020 | S · Sale | −1.29K | $58.38 | $75.37K | 0.1% | 920.74K | 919.45K |
| Common Stock Indirect | 1/10/2020 | S · Sale | −1.73K | $58.83 | $102.01K | 0.2% | 919.45K | 917.72K |
| Common Stock Indirect | 1/13/2020 | S · Sale | −7.91K | $52.49 | $414.99K | 0.9% | 917.72K | 909.81K |
| Common Stock Indirect | 1/13/2020 | S · Sale | −10.19K | $53.11 | $541.40K | 1.1% | 909.81K | 899.62K |
| Common Stock Indirect | 1/13/2020 | S · Sale | −400.00 | $54.21 | $21.68K | 0.0% | 899.62K | 899.22K |
| Common Stock Indirect | 1/14/2020 | S · Sale | −3.39K | $52.44 | $177.77K | 0.4% | 899.22K | 895.83K |
| Common Stock Indirect | 1/14/2020 | S · Sale | −5.01K | $53.30 | $266.98K | 0.6% | 895.83K | 890.82K |
| Common Stock Indirect | 1/14/2020 | S · Sale | −10.10K | $54.06 | $546.06K | 1.1% | 890.82K | 880.72K |
| Total | −55.50K | -$3.04M | ||||||
Common Stock
Direct| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.30M | Direct |
| Total | 1.30M | 1.30M direct |